<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Skye Bioscience, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock</link>
<description>Latest news and press releases for Skye Bioscience, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/skye-bioscience-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c05578dffbe2df11872b.webp</url>
<title>Skye Bioscience, Inc. Common Stock</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock</link>
</image>
<item>
<title>Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-presenting-at-glp-1-based-therapeutics-summit</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-presenting-at-glp-1-based-therapeutics-summit</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new</description>
</item>
<item>
<title>Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-exposure-response-to-inform-phase-2b-dose-selection-for-glp-1-combination-development-6</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-exposure-response-to-inform-phase-2b-dose-selection-for-glp-1-combination-development-6</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study SAN DIEGO, April 02, 2026 (GLOBE</description>
</item>
<item>
<title>Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-33</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-33</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV</description>
</item>
<item>
<title>Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-to-announce-2025-financial-results-and-business-update-on-march-10-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-to-announce-2025-financial-results-and-business-update-on-march-10-2026-6</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new</description>
</item>
<item>
<title>HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/halozyme-reports-full-year-2025-record-revenue-of-dollar14-billion-and-reiterates-strong-2026-financial-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/halozyme-reports-full-year-2025-record-revenue-of-dollar14-billion-and-reiterates-strong-2026-financial-guidance</guid>
<pubDate>Tue, 17 Feb 2026 21:01:00 GMT</pubDate>
<description>Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities.</description>
</item>
<item>
<title>Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-reports-positive-cbeyond-phase-120000369</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-reports-positive-cbeyond-phase-120000369</guid>
<pubDate>Mon, 02 Feb 2026 12:00:00 GMT</pubDate>
<description>22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab dosesWeight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantageStrong safety and tolerability profile maintained — no</description>
</item>
<item>
<title>Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-highlights-attributes-peripherally-120000194</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-highlights-attributes-peripherally-120000194</guid>
<pubDate>Thu, 29 Jan 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model" at Keystone’s conference, Obesity Therapeutics: Unlo</description>
</item>
<item>
<title>Skye Bioscience to Present Poster at Keystone Obesity Conference</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-present-poster-keystone-120000567</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-present-poster-keystone-120000567</guid>
<pubDate>Wed, 21 Jan 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a poster at Keystone’s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects. Skye’s presentation addresses the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody: Can nimacimab enhance opt</description>
</item>
<item>
<title>Skye Provides 2026 Corporate Outlook</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-provides-2026-corporate-outlook-120000363</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-provides-2026-corporate-outlook-120000363</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate favorable safety profile.CBeyond Phase 2a topline results to 52 weeks including 13-week off-therapy follow-up period expected in Q3 2026. Phase 2b (CBeyond 2) plan to be finalized in Q1; trial launch targeted for Q3 2026. SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Sky</description>
</item>
<item>
<title>Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/halozyme-skye-bioscience-announce-global-120000675</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/halozyme-skye-bioscience-announce-global-120000675</guid>
<pubDate>Mon, 05 Jan 2026 12:00:00 GMT</pubDate>
<description>Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimabSAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye has licensed Halozyme's ENHANZE® drug delivery technology for the development and potential commerci</description>
</item>
<item>
<title>Skye Bioscience to Participate in Upcoming Investment Conferences</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-participate-upcoming-investment-120000035</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-participate-upcoming-investment-120000035</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences:Citi Global Healthcare Conference (Miami)1x1 meetings: Dec. 2Evercore Annual Healthcare Conference (Coral Gables)Fireside Chat: Dec. 3, 12:55 pm ET1x1 meetingsPiper Sandler Annual Healthcare</description>
</item>
<item>
<title>Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-reports-third-quarter-210100961</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-reports-third-quarter-210100961</guid>
<pubDate>Mon, 10 Nov 2025 21:01:00 GMT</pubDate>
<description>Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a clean neuropsychiatric safety profile and no increase in gastrointestinal adverse events.Nimacimab plus semaglutide showed additional reduction in waist circumference of -3.2 cm vs. semaglutide alone.Rebound weight gain was lower in the 12-week post-treatment follow-up period in patients treated wi</description>
</item>
<item>
<title>Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-breaking-oral-abstract-120500628</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-breaking-oral-abstract-120500628</guid>
<pubDate>Wed, 05 Nov 2025 12:05:00 GMT</pubDate>
<description>During 12-week post-treatment period, nimacimab plus semaglutide blunts weight regain compared to semaglutide alone in subset analysisSAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will present a late-breaking oral presentation at ObesityWeek 2025 on November 7, 2025, in Atlanta, Georgia. The pr</description>
</item>
<item>
<title>Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-announce-third-quarter-120000976</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-announce-third-quarter-120000976</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Monday, November 10, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its third quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day. The live webca</description>
</item>
<item>
<title>Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-reports-topline-cbeyond-110000995</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-reports-topline-cbeyond-110000995</guid>
<pubDate>Mon, 06 Oct 2025 11:00:00 GMT</pubDate>
<description>Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.Clinically meaningful additional weight loss observed with combination of nimacimab, a peripheral CB1 inhibitor, and semaglutide compared to semaglutide alone.Nimacimab alone and in combination demonstrated a clean safety profile, with no added gastrointestinal adverse events and</description>
</item>
<item>
<title>Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-presents-phase-1b-data-110000005</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-presents-phase-1b-data-110000005</guid>
<pubDate>Fri, 19 Sep 2025 11:00:00 GMT</pubDate>
<description>Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerabilitySAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (</description>
</item>
<item>
<title>Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-cb1-inhibitor-nimacimab-demonstrates-110000018</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-cb1-inhibitor-nimacimab-demonstrates-110000018</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>Skye shares new preclinical DIO data at virtual KOL eventNimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment weight loss compared to tirzepatideNimacimab reduced rebound weight gain following treatment with tirzepatide or nimacimab + tirzepatideNimacimab outperformed monlunabant head-to-head, and is uniquely positioned as a well-tolerated therapeutic to potentially induce healthier and sustained weight loss,</description>
</item>
<item>
<title>Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-completes-26-week-treatment-110000942</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-completes-26-week-treatment-110000942</guid>
<pubDate>Tue, 02 Sep 2025 11:00:00 GMT</pubDate>
<description>Skye also announces completion of enrollment of 26‑week extension study; 52‑week data planned, with post‑extension 13‑week follow‑upSAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the last patient has completed 26 weeks of treatment in the main study of its Phase 2a CBeyond™ clinical trial evaluati</description>
</item>
<item>
<title>Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-host-virtual-kol-110000278</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-host-virtual-kol-110000278</guid>
<pubDate>Wed, 27 Aug 2025 11:00:00 GMT</pubDate>
<description>Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a virtual KOL event, titled “Expert Panel on Peripheral CB1 Inhibition as a Mechanism for Weight Loss,” on Thursday, September 4th at 8:00 AM ET, to discuss expectations and details of upcom</description>
</item>
<item>
<title>Skye Bioscience to Participate in Upcoming Investment and Medical Conferences</title>
<link>https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-participate-upcoming-investment-110000645</link>
<guid isPermaLink="true">https://6ix.com/company/skye-bioscience-inc-common-stock/news/skye-bioscience-participate-upcoming-investment-110000645</guid>
<pubDate>Thu, 21 Aug 2025 11:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming investment and medical conferences: Investment Conferences Cantor Global Healthcare Conference (New York)Fireside Chat Sept. 5 8:00 am ET + 1x1 meetings H.C. Wainwright Global Investment Conference (New Yor</description>
</item>
</channel>
</rss>